title: MicroRNA-378 inhibits cell growth and enhances L-OHP-induced apoptosis in human colorectal cancer.
abstract: MicroRNAs (miRNAs) are small noncoding RNAs that participate in a variety of biological processes, and dysregulation of miRNAs is widely associated with cancer development and progression. MiR-378 is frequently downregulated in colorectal cancer (CRC) and colorectal cell lines; however, it has high serum levels. Bioinformatics analysis further deduced that CDC40 is a potential target of miR-378, and luciferase reporter assays confirmed the direct regulation of CDC40 by miR-378. CDC40 plays a key role in cell cycle progression through G1/S and G2/M and pre-mRNA splicing. Subsequently, we determined that miR-378 inhibits cell growth and the G1/S transition in CRC cells and that these effects were CDC40-dependent. Finally, miR-378 increased cell apoptosis induced by the chemotherapeutic drug L-OHP. Our data highlight the potential application of miR-378 as a tumor suppressor for CRC therapy and overcoming chemoresistance, and it may also be a potential tumor marker for CRC prognosis.
authors.affiliation: Department of Gastrointestinal Surgery, China-Japan Union Hospital of Jilin University, Changchun, China; Department of General Surgery, Affiliated Hospital of Beihua University, Jilin, China.
authors.forename: Kai-Yu
authors.initials: KY
authors.lastname: Wang
authors.forename: Jun
authors.initials: J
authors.lastname: Ma
authors.forename: Fu-Xi
authors.initials: FX
authors.lastname: Zhang
authors.forename: Ming-Jun
authors.initials: MJ
authors.lastname: Yu
authors.forename: Ji-Shan
authors.initials: JS
authors.lastname: Xue
authors.forename: Ji-Sheng
authors.initials: JS
authors.lastname: Zhao
mesh_terms: D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D014408:Biomarkers, Tumor / Q000097:blood; D015153:Blotting, Western; D059447:Cell Cycle Checkpoints / Q000502:physiology*; D018797:Cell Cycle Proteins / Q000378:metabolism; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000378:metabolism*; D019295:Computational Biology; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D053208:Kaplan-Meier Estimate; D008156:Luciferases; D035683:MicroRNAs / Q000097:blood / Q000378:metabolism*; D009944:Organoplatinum Compounds / Q000494:pharmacology; D000077150:Oxaliplatin; D000072260:RNA Splicing Factors; D016601:RNA-Binding Proteins / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D013778:Tetrazolium Salts; D013844:Thiazoles
chemical_list: D014408:Biomarkers, Tumor; C112200:CDC40 protein, human; D018797:Cell Cycle Proteins; C526012:MIRN378 microRNA, human; D035683:MicroRNAs; D009944:Organoplatinum Compounds; D000072260:RNA Splicing Factors; D016601:RNA-Binding Proteins; D013778:Tetrazolium Salts; D013844:Thiazoles; D000077150:Oxaliplatin; D008156:Luciferases; C022616:thiazolyl blue
keywords: CDC40; chemoresistance; colorectal cancer; miR-378; microRNA